4SC 202

Drug Profile

4SC 202

Alternative Names: 4SC-202

Latest Information Update: 09 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nycomed
  • Developer 4SC
  • Class Antineoplastics; Benzamides; Pyrazoles; Pyrroles; Small molecules; Sulfones
  • Mechanism of Action Bromodomain and extraterminal domain protein modulators; HDAC1 protein inhibitors; HDAC2 protein inhibitors; HDAC3 protein inhibitors; Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Haematological malignancies
  • Preclinical Cancer; Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 02 Jun 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 16 May 2017 4SC plans a phase II trial for skin cancer and gastrointestinal cancer (Combination therapy, Second-line therapy or greater)
  • 11 Apr 2017 Preclinical trials in Pancreatic cancer in Germany (PO) before April 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top